Haemonetics Corporation $HAE Shares Acquired by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC lifted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 3.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,216 shares of the medical instruments supplier’s stock after acquiring an additional 214 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Haemonetics were worth $464,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Royce & Associates LP increased its stake in shares of Haemonetics by 0.7% during the first quarter. Royce & Associates LP now owns 1,161,296 shares of the medical instruments supplier’s stock valued at $73,800,000 after acquiring an additional 8,028 shares during the period. Boston Trust Walden Corp increased its stake in shares of Haemonetics by 22.1% during the first quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier’s stock valued at $71,070,000 after acquiring an additional 202,609 shares during the period. Royal Bank of Canada increased its stake in shares of Haemonetics by 2.3% during the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after acquiring an additional 24,650 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Haemonetics by 20.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier’s stock valued at $60,888,000 after acquiring an additional 165,118 shares during the period. Finally, Citigroup Inc. grew its position in Haemonetics by 87.3% in the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock worth $39,755,000 after buying an additional 291,574 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Down 2.3%

NYSE HAE opened at $48.63 on Thursday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of 14.87, a PEG ratio of 0.92 and a beta of 0.37. The firm’s 50 day moving average price is $52.07 and its two-hundred day moving average price is $62.89.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $321.39 million for the quarter, compared to analysts’ expectations of $305.12 million. During the same period in the previous year, the company posted $1.02 EPS. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Robert W. Baird assumed coverage on shares of Haemonetics in a research report on Thursday, June 26th. They issued an “outperform” rating and a $87.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Haemonetics in a research report on Wednesday, October 8th. Raymond James Financial lowered shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price target for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Barrington Research restated an “outperform” rating and issued a $86.00 price target on shares of Haemonetics in a research report on Tuesday, September 23rd. Finally, Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Wednesday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $75.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.